Osteoporosis - Pipeline Review, H2 2020

October 2020 | 375 pages | ID: O01E16645AEEN
Global Markets Direct

Abstracts

Osteoporosis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 9, 8, 22, 4, 64, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Osteoporosis - Overview
Osteoporosis - Therapeutics Development
Osteoporosis - Therapeutics Assessment
Osteoporosis - Companies Involved in Therapeutics Development
Osteoporosis - Drug Profiles
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Osteoporosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Osteoporosis - Pipeline by Ablynx NV, H2 2020
Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2020
Osteoporosis - Pipeline by Addpharma Inc, H2 2020
Osteoporosis - Pipeline by Aerami Therapeutics, H2 2020
Osteoporosis - Pipeline by Affilogic SAS, H2 2020
Osteoporosis - Pipeline by AgeX Therapeutics Inc, H2 2020
Osteoporosis - Pipeline by AlphaMab Co Ltd, H2 2020
Osteoporosis - Pipeline by Amgen Inc, H2 2020
Osteoporosis - Pipeline by Angitia Biopharmaceuticals, H2 2020
Osteoporosis - Pipeline by Aryogen Pharmed Co, H2 2020
Osteoporosis - Pipeline by Axsome Therapeutics Inc, H2 2020
Osteoporosis - Pipeline by Bainan Biotech ApS, H2 2020
Osteoporosis - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
Osteoporosis - Pipeline by BIOCND Inc, H2 2020
Osteoporosis - Pipeline by Biosion Inc, H2 2020
Osteoporosis - Pipeline by Bone Biologics Corp, H2 2020
Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2020
Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, H2 2020
Osteoporosis - Dormant Projects, H2 2020
Osteoporosis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Osteoporosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020